Christine A. Poon, a director at Regeneron Pharmaceuticals, has reported several stock transactions that occurred on November 2, 2026. This filing is significant as it highlights the ongoing engagement of company insiders in the stock market, reflecting their confidence and strategic movements within the company.

Background

Regeneron Pharmaceuticals, Inc. is a prominent player in the pharmaceutical industry, specifically categorized under Pharmaceutical Preparations. The company is headquartered in Tarrytown, New York, and is known for its innovative drug development and research. Poon's recent filing follows a series of disclosures, indicating her active role in managing her stock portfolio.

What the Filing Says

The recent filing, dated November 4, 2026, details multiple transactions by Poon. On November 2, she acquired 7,830 shares of Regeneron common stock at a price of $376.69 per share. Additionally, she disposed of shares in several transactions, including:

"218 shares at $966.74, 772 shares at $967.38, 2,499 shares at $968.58, 3,203 shares at $969.50, 937 shares at $970.51, and 201 shares at $971.31."

Following these transactions, Poon's ownership in Regeneron stands at 12,831 shares.

Impact

Poon's transactions may influence investor sentiment regarding Regeneron Pharmaceuticals. As a director, her stock activity can signal confidence in the company's future performance. This is particularly relevant in the pharmaceutical sector, where insider trading can impact market perceptions and stock valuations.

What's Next

The filing does not say what happens next.